Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on August 14, 2015. The report addresses a regulatory notice received from Nasdaq regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing references the Company's Form 10-Q for the period ended June 30, 2015, which reported stockholders' equity of $2,373,371. The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity beyond this equity figure.
Material Changes and Listing Status
On August 14, 2015, the Company received notice from Nasdaq indicating a failure to satisfy Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity for continued listing. The reported equity of $2,373,371 falls below this threshold.
Outlook, Management Commentary, and Risks
The Company has until September 28, 2015, to submit a plan to Nasdaq to regain compliance with the listing rule. Management intends to provide this plan within the allotted timeframe. The primary risk identified is the potential delisting if compliance is not achieved.
Key Facts for Investor Verification
- Stockholders' equity as of June 30, 2015, was $2,373,371, below the $2,500,000 Nasdaq requirement.
- The Company must submit a compliance plan to Nasdaq by September 28, 2015.
- Failure to regain compliance may result in the delisting of the Company's stock from Nasdaq.